Karyopharm Therapeutics Inc. Business Finance Contracts & Agreements
26 Contracts & Agreements
- Exchange Agreements (1 contract)
- Financing Agreements (1)
- Guarantee Agreements (1)
- Indenture Agreements (1)
- Investor Rights Agreements (1)
- Purchase Agreements (3)
- Registration Rights Agreements (1)
- Stock Agreements (9)
- Underwriting Agreements (6)
- Warrant Agreements (2)
- Common Stock Purchase Warrant, dated August 1, 2023, issued to Heathcare Royalty Partners III, L.P (Filed With SEC on August 2, 2023)
- Registration Rights Agreement, dated December 5, 2022, by and among the Company and the other parties thereto (Filed With SEC on December 5, 2022)
- Securities Purchase Agreement, dated December 5, 2022, by and among the Company and the other parties thereto (Filed With SEC on December 5, 2022)
- Form of Warrant to Purchase Common Stock to be issued pursuant to the Securities Purchase Agreement (Filed With SEC on December 5, 2022)
- Amendment to Asset Purchase Agreement, dated as of July 17, 2019, by and between the Registrant and Biogen MA Inc (Filed With SEC on November 3, 2021)
- Form of Nonstatutory Stock Option Agreement for Inducement Grants adopted August 25, 2020 (Filed With SEC on November 2, 2020)
- Underwriting Agreement, dated March 3, 2020, by and among the Company, J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and Jefferies LLC (Filed With SEC on March 4, 2020)
- Revenue Interest Financing Agreement, dated September 14, 2019, between the Registrant and HealthCare Royalty Partners III, L.P, and HealthCare Royalty Partners IV, L.P (Filed With SEC on November 4, 2019)
- Nonstatutory Stock Option Agreement, dated February 25, 2019, between the Company and Michael Mason (Filed With SEC on February 25, 2019)
- Indenture (including form of Note) with respect to the Companys 3.00% convertible senior notes due 2025, dated as of October 16, 2018, between the Company and Wilmington Trust,... (Filed With SEC on October 16, 2018)
- Parent Company Guarantee, dated May 23, 2018, by Antengene Corporation Co. Ltd (Filed With SEC on August 7, 2018)
- Form of Nonstatutory Stock Option Agreement for Inducement Grants (Filed With SEC on May 10, 2018)
- Asset Purchase Agreement, dated January 24, 2018, by and between Biogen MA Inc. and the Registrant (Filed With SEC on May 10, 2018)
- Underwriting Agreement, dated May 2, 2018, by and among the Company, J.P. Morgan Securities LLC, Jefferies LLC and Leerink Partners LLC (Filed With SEC on May 3, 2018)
- Nonstatutory Stock Option Agreement, dated September 11, 2017, between the Company and Mr. Falvey (Filed With SEC on September 12, 2017)
- KARYOPHARM THERAPEUTICS INC. (aDelaware corporation) 3,902,439 Shares of Common Stock UNDERWRITING AGREEMENT (Filed With SEC on April 26, 2017)
- KARYOPHARM THERAPEUTICS INC. Shares of Common Stock (par value$0.0001 per share) Controlled Equity OfferingSM Sales Agreement (Filed With SEC on December 8, 2015)
- KARYOPHARM THERAPEUTICS INC. RESTRICTED STOCK UNIT AGREEMENT (Filed With SEC on November 9, 2015)
- KARYOPHARM THERAPEUTICS INC. (aDelaware corporation) 3,000,000 Shares of Common Stock UNDERWRITING AGREEMENT (Filed With SEC on January 8, 2015)
- KARYOPHARM THERAPEUTICS INC. (a Delaware corporation) [ ] Shares of Common Stock UNDERWRITING AGREEMENT (Filed With SEC on June 25, 2014)
- KARYOPHARM THERAPEUTICS INC. 2013 EMPLOYEE STOCK PURCHASE PLAN October 8, 2013 (Filed With SEC on October 28, 2013)
- KARYOPHARM THERAPEUTICS INC. NONSTATUTORY STOCK OPTION AGREEMENT (Filed With SEC on October 28, 2013)
- KARYOPHARM THERAPEUTICS INC. (a Delaware corporation) Shares of Common Stock UNDERWRITING AGREEMENT (Filed With SEC on October 28, 2013)
- Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. RESEARCH AGREEMENT (Filed With SEC on October 4, 2013)
- KARYOPHARM THERAPEUTICS INC. NON-QUALIFIED STOCK OPTION AGREEMENT (Filed With SEC on October 4, 2013)
- KARYOPHARM THERAPEUTICS INC. THIRD AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT July 26, 2013 (Filed With SEC on October 4, 2013)
